A Phase 3 interventional study of Ranibizumab in Age-related Macular Degeneration, sponsored by Genentech, Inc.. Completed at 99 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-01-18.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 3rd largest by enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2009, is one of 31 in phase 3, and was the 46th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,097 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
32 studies in Macular Degeneration by Hoffmann-La Roche: 3 open now, 10 under way, 4 of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 32 studies in Macular Degeneration by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2009, is one of 14 in phase 3, and was the 8th registered.
Hoffmann-La Roche’s Macular Degeneration studies by the year they started, since 2002.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Hoffmann-La Roche’s 32 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular Inclusion Criteria (Study Eye)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
Drug: Ranibizumab
Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.
Drug: Ranibizumab
Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
Drug: Ranibizumab
Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.
Drug: Ranibizumab
Sterile solution for intravitreal injection.
Also known as: Lucentis
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.
Time frame: Baseline to Month 12
Number of Ranibizumab Injections up to But Not Including Month 12
Time frame: Baseline to Month 12
Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
Time frame: Baseline to Month 12
Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12
VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.
Time frame: Month 12
Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12
The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness \< 270 µm.
Time frame: Month 12
Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).
Time frame: Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).
Time frame: Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12
The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm\^2.
Time frame: Baseline to Month 12
| Milestone | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Started | 275 | 274 | 275 | 273 |
| Completed | 258 | 258 | 263 | 258 |
| Not completed | 17 | 16 | 12 | 15 |
| Withdrew: Adverse event | 2 | 0 | 2 | 0 |
| Withdrew: Death | 8 | 5 | 4 | 5 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 | 2 |
| Withdrew: Physician's decision to withdraw patient | 1 | 0 | 0 | 0 |
| Withdrew: Patient's decision to withdraw | 4 | 9 | 4 | 8 |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.
| Letters | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 | 10.1 ± 13.3 | 9.2 ± 14.6 | 8.2 ± 13.3 | 8.6 ± 13.8 |
| Injections | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Number of Ranibizumab Injections up to But Not Including Month 12 | 11.3 ± 1.8 | 11.2 ± 2.1 | 7.7 ± 2.7 | 6.9 ± 2.4 |
BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.
| Percentage of patients | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12 | 34.5 (28.9 to 40.2) | 36.1 (30.4 to 41.8) | 30.2 (24.8 to 35.6) | 33.0 (27.4 to 38.5) |
VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.
| Percentage of patients | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12 | 52.4 (46.5 to 58.3) | 50.0 (44.1 to 55.9) | 46.2 (40.3 to 52.1) | 43.6 (37.7 to 49.5) |
The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness \< 270 µm.
| Percentage of patients | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12 | 5.1 (2.5 to 7.7) | 5.8 (3.1 to 8.6) | 2.9 (0.9 to 4.9) | 4.8 (2.2 to 7.3) |
Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).
| µm | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Day 7 | -104.9 ± 130.3 | -84.9 ± 111.3 | -103.5 ± 141.3 | -100.6 ± 123.4 |
| Month 1 | -141.5 ± 137.5 | -128.6 ± 133.3 | -132.6 ± 148.2 | -146.0 ± 144.3 |
| Month 2 | -152.5 ± 142.4 | -140.3 ± 131.1 | -142.9 ± 141.6 | -156.9 ± 145.0 |
| Month 3 | -157.0 ± 143.8 | -147.9 ± 134.3 | -154.5 ± 147.9 | -164.9 ± 144.5 |
| Month 4 | -164.0 ± 146.6 | -151.8 ± 143.3 | -142.7 ± 153.6 | -159.7 ± 148.8 |
| Month 6 | -162.0 ± 150.0 | -149.2 ± 144.0 | -147.5 ± 151.9 | -159.1 ± 149.6 |
| Month 9 | -164.5 ± 151.8 | -153.1 ± 144.8 | -153.5 ± 147.1 | -157.8 ± 155.6 |
| Month 12 | -172.0 ± 150.5 | -163.3 ± 142.6 | -161.2 ± 152.3 | -172.4 ± 148.6 |
Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).
| mm^3 | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Day 7 | -0.79 ± 0.80 | -0.80 ± 0.76 | -0.72 ± 0.87 | -0.81 ± 0.76 |
| Month 1 | -1.26 ± 1.06 | -1.30 ± 1.15 | -1.16 ± 1.03 | -1.38 ± 1.18 |
| Month 2 | -1.34 ± 1.17 | -1.49 ± 1.31 | -1.30 ± 1.13 | -1.47 ± 1.25 |
| Month 3 | -1.42 ± 1.25 | -1.51 ± 1.32 | -1.43 ± 1.33 | -1.55 ± 1.28 |
| Month 4 | -1.42 ± 1.22 | -1.56 ± 1.31 | -1.31 ± 1.24 | -1.48 ± 1.27 |
| Month 6 | -1.47 ± 1.25 | -1.61 ± 1.34 | -1.35 ± 1.33 | -1.48 ± 1.36 |
| Month 9 | -1.55 ± 1.41 | -1.67 ± 1.34 | -1.35 ± 1.31 | -1.48 ± 1.33 |
| Month 12 | -1.54 ± 1.31 | -1.66 ± 1.37 | -1.41 ± 1.36 | -1.49 ± 1.35 |
The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm\^2.
| Disc area units | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Change in the total area of CNV | -2.14 ± 2.40 | -2.42 ± 2.38 | -1.74 ± 2.22 | -1.98 ± 2.39 |
| Change in the total area of CNV leakage | -2.35 ± 2.39 | -2.63 ± 2.34 | -2.01 ± 2.28 | -2.22 ± 2.48 |
Collected over Adverse events were recorded from Baseline (first treatment day) through Month 12.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg Monthly | — | 66/274 (24.1%) | 240/274 (87.6%) |
| Ranibizumab 2.0 mg Monthly | — | 54/274 (19.7%) | 243/274 (88.7%) |
| Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | — | 57/275 (20.7%) | 250/275 (90.9%) |
| Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | — | 54/272 (19.9%) | 239/272 (87.9%) |
| Event | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 6/274 | 1/274 | 2/275 | 2/272 |
| PneumoniaInfections and infestations | 5/274 | 5/274 | 6/275 | 3/272 |
| Myocardial infarctionCardiac disorders | 5/274 | 1/274 | 0/275 | 3/272 |
| Atrial fibrillationCardiac disorders | 2/274 | 1/274 | 4/275 | 4/272 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/274 | 0/274 | 1/275 | 4/272 |
| FallInjury, poisoning and procedural complications | 1/274 | 2/274 | 1/275 | 3/272 |
| Hip fractureInjury, poisoning and procedural complications | 1/274 | 1/274 | 3/275 | 3/272 |
| Cardiac arrestCardiac disorders | 3/274 | 0/274 | 0/275 | 1/272 |
| Visual acuity reducedEye disorders | 0/274 | 3/274 | 2/275 | 0/272 |
| DehydrationMetabolism and nutrition disorders | 3/274 | 1/274 | 1/275 | 0/272 |
| Event | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) |
|---|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 63/274 | 51/274 | 48/275 | 41/272 |
| Vitreous detachmentEye disorders | 22/274 | 21/274 | 16/275 | 27/272 |
| SinusitisInfections and infestations | 12/274 | 7/274 | 27/275 | 8/272 |
| Vitreous floatersEye disorders | 26/274 | 15/274 | 11/275 | 17/272 |
| Eye painEye disorders | 15/274 | 25/274 | 16/275 | 23/272 |
| Vitreous detachmentEye disorders | 20/274 | 24/274 | 17/275 | 13/272 |
| NasopharyngitisInfections and infestations | 17/274 | 10/274 | 17/275 | 23/272 |
| FallInjury, poisoning and procedural complications | 14/274 | 12/274 | 8/275 | 21/272 |
| HypertensionVascular disorders | 14/274 | 20/274 | 21/275 | 15/272 |
| Macular degenerationEye disorders | 12/274 | 8/274 | 18/275 | 15/272 |
| Age Continuous(years) | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Total |
|---|---|---|---|---|---|
| Mean | 78.8 ± 8.4 | 79.3 ± 8.3 | 78.5 ± 8.3 | 78.3 ± 8.3 | 78.7 ± 8.3 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg Monthly | Ranibizumab 2.0 mg Monthly | Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN]) | Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN]) | Total |
|---|---|---|---|---|---|
| Female | 162 | 170 | 163 | 156 | 651 |
| Male | 113 | 104 | 112 | 117 | 446 |
The record gives a start of Jul 2009, a primary completion of Aug 2011 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab